Reality check: primary vascular access creation today

Jann Tabitha, Wyss Thomas R., Gahl Brigitta, Kalicki Robert M., Uehlinger Dominik E., Widmer Matthias K.

a Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Switzerland

b Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Switzerland

Summary
INTRODUCTION: In Switzerland, the outcome of vascular access creation in the 4500 current dialysis patients is unknown, mainly because there is no prospective registry for patients undergoing vascular access surgery for renal replacement therapy. The aim of the study was to assess the quality of vascular access creation and to compare it with the current literature and guidelines, in order to define strategies to improve clinical outcome.

METHODS: Retrospective single-centre study in a tertiary referral centre. All consecutive patients over 18 years of age undergoing primary vascular access creation between January 2013 and December 2014 were included. Follow-up data for at least 12 months were collected.

RESULTS: During the study period, 365 patients had a surgical intervention for renal replacement therapy. A primary vascular access was created in 74 patients (20%), who were further analysed in our study: 63 (85%) had an arteriovenous fistula (AVF) and 11 (15%) an arteriovenous graft (AVG). The intervention-free survival (primary patency rate) of the primary vascular access at 1 year was 46% (95% confidence interval [CI] 33–58%) for AVF and 30% (95% CI 7–58%) for AVG, with a secondary patency rate at 1 year of 75% (95% CI 63–84%) for AVF and 50% (95% CI 18–75%) for AVG. Twenty-seven patients (36%) with primary vascular access underwent central venous catheter (CVC) placement (tunnelled or non-tunnelled) before the access creation. Thirty-seven (50%) patients had their first dialysis through a CVC. Thirty-one patients (42%) never received a CVC.

CONCLUSIONS: The primary patency of vascular access was unexpectedly low, and the number of CVC requests unexpectedly high. In light of this, we consider it essential that centres creating vascular access should register their activities and compare their outcomes with current guidelines to check and improve clinical management. To facilitate this, there is an initiative starting in 2018 encouraging all Swiss vascular surgeons to provide data on vascular access interventions, including 1-year follow-up, in the national online registry “SwissVasc 2.0”.

Keywords: outcome of primary vascular access for dialysis, arteriovenous fistula, arteriovenous graft, primary patency of vascular access for dialysis, guidelines vascular access

Introduction
Functional vascular access, most commonly an arteriovenous fistula (AVF) or an arteriovenous graft (AVG), is essential to deliver adequate haemodialysis therapy to patients. The need for dialysis in patients with chronic kidney disease has been increasing in recent years [1]. Between 1990 and 2000, the global prevalence of maintenance dialysis increased 1.7 times and the incidence more than doubled [2]. Therefore, efficient vascular access creation and maintenance service is essential. With an average life expectancy of patients on dialysis of 5 to 10 years, vascular access longevity is an important issue and unfortunately can be jeopardised by various issues [3]. Non-maturation, occlusion and infection are typical complications occurring during the evolution of the vascular access. This results in frequent surgical revisions and an increased use of central venous catheters (CVCs) as an alternative for haemodialysis access, which in turn is related to higher morbidity and mortality rates and increased costs [4–8]. The primary patency of a vascular access, which represents intervention-free survival, has been reported to be superior for AVFs [9–13], with AVGs and CVCs showing a reduced intervention-free survival. There is conflicting evidence in the literature as to primary AVF creation rates, ranging from 24% to 80% [14], and the percentage of patients on CVC dialysis is reported to be nearly 80% [15].

The optimal surgical management is to create an AVF, and avoid grafts and CVCs for as long as possible. It remains unclear whether this aim is being achieved in current practice. Vascular access guidelines such as the Kidney Disease Outcomes Quality Initiative (K/DOQI) [16], European Renal Best Practice Guidelines [14] and the Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS) [17] address this issue.

The United States Renal Data System (USRDS) collects data from national and regional renal registries in the USA [1]. However, Switzerland does not have a specific multidisciplinary registry for vascular access and outcome data.

Correspondence:
Matthias Kurt Widmer, MD, MME (unibe), Department of Cardiovascular Surgery, Inselspital, University of Bern, CH-3010 Bern, matthias.widmer[at]insel.ch
for vascular access creation is not available, although more than 4500 patients are currently on haemodialysis in this country [18]. This means that we cannot compare our results with other centres and countries or review conformity with guidelines.

The aim of this retrospective study was to assess the quality of vascular access creation in a Swiss tertiary referral centre and to compare it with the current literature and guidelines to define strategies to improve the clinical management process (fig. 1).

**Methods**

This retrospective analysis was designed as a quality control study of a tertiary referral centre in Switzerland, in accordance with the Helsinki declaration. All consecutive patients >18 years old undergoing primary vascular access creation between January 2013 and December 2014 were included. Other interventions for renal replacement therapy during this time (isolated catheters for peritoneal dialysis, CVCs without simultaneous access creation, secondary vascular access creation and vascular access revisions) were taken into account but not further analysed. Data, including demographics, risk factors, comorbidities, surgical details, outcome parameters and follow-up information, were retrieved from the hospital records of the Department of Cardiovascular Surgery and the Department of Nephrology and Hypertension. We contacted external dialysis units for information on patients followed up at other institutions. Primary vascular access was classified as AVF or AVG, as well as according to its anatomical location. Study data were collected and managed using REDCap electronic data capture hosted at the institution (REDCap Software, Version 6.9.3, Vanderbilt University). Follow-up data for at least 365 days were collected. Data were collected in a retrospective manner as part of the in-hospital quality control, which is regulated by the federal law for health insurance. Primary endpoints of the study were the primary and the secondary patency after 1 year. Secondary endpoints were reinterventions and CVC placement.

Proportions and 95% confidence intervals (CIs) of primary and secondary endpoints at 1 year after vascular access were calculated to compare the treatment groups using the chi-squared test. The Kaplan-Meier method was used to estimate freedom from events with respect to all endpoints during the entire follow-up time. Hazard ratios and 95% CIs were analysed using Cox regression analysis. The proportional hazard assumption was tested on Schoenfeld residuals. All CIs are two-sided. Statistical analyses were performed using Stata 12 (StataCorp LP, College Station, TX, USA).

The ESVS definitions of primary and secondary patency were applied [17]. In brief, primary patency is the time between access creation and the first reintervention. Secondary patency is the time between access creation and abandonment after one or more reinterventions.

**Results**

**General aspects**

Between January 2013 and December 2014, there were 365 surgical interventions for renal replacement therapy (fig. 2). Revision surgery represents the largest group (n = 163), followed by CVC placement (n = 78), including 45 exchanges from a non-tunnelled to a tunnelled CVC, 15 isolated tunnelled CVCs and 18 CVC removals. Seventy-four patients with a primary vascular access creation were included in the further analysis: 11 AVG and 63 AVF. Nine patients with a primary access were excluded because of renal transplantation (three), operative abandonment of access (four), no further dialysis required (one), and patient refusal of revision of a failing vascular access (one).

All patients had preoperative venous and arterial ultrasound mapping. The surgeons’ experience was as follows: trainees under supervision (15) and board-certified surgeons (59). Type of anaesthesia used was: local (2), regional (53), and general (19).
Demographics

Table 1 shows demographic data and comorbidities of patients with a primary vascular access creation. The most common cause of end-stage renal disease was hypertensive nephropathy (36%).

Follow-up and Survival

Mean follow-up ± standard deviation was 564 ± 294 days. The survival curve is shown in fig. 3. Mortality at 1 year was 11%.

Primary patency rate

The intervention-free primary patency rate of the vascular access at 1 year was 46% (95% CI 33–58%) for AVF and 30% (95% CI 7–58%) for AVG (fig. 4). There was no significant difference in primary patency rate between AVG and AVF either in the upper arm (30%, 95% CI 7–58% vs 46%, 95% CI 24–66%, respectively; p = 0.384) or in the forearm (30%, 95% CI 7–58% vs 46%, 95% CI 30–60%, respectively; p = 0.813). A Cox regression analysis showed hazard ratios for primary patency of 0.91 (95% CI 0.41–1.99) for forearm AVF and 0.68 (95% CI 0.28–1.66) for upper arm AVF, when compared with AVG.

Secondary patency rate and reinterventions

The secondary patency rate of the vascular access at 1 year was 75% (95% CI 63–84%) for AVF and 50% (95% CI 18–75%) for AVG (fig. 5). A trend to a better secondary patency rate at 1 year was seen with AVF in the upper arm (80%, 95% CI 56–92%) as compared with AVF on the forearm (73%, 95% CI 56–84%; p = 0.322). A Cox regression analysis showed hazard ratios for secondary patency of 0.77 (95% CI 0.28–2.12) for forearm AVF and 0.46 (95% CI 0.13–1.6) for upper arm AVF, when compared with AVG.

Table 2 shows revisions performed during the follow-up. Twenty-four percent (16/68) of all revisions were per-

![Figure 3: Patient survival after vascular access creation (including 95% confidence intervals): median survival 528 days (interquartile range 371–807).](image3)

![Figure 4: Primary patency of primary vascular access: median primary patency 253.5 days (interquartile range 92–453).AVF = arteriovenous fistula; AVG = arteriovenous graft](image4)

Table 1: Demographics and comorbidities.

<table>
<thead>
<tr>
<th>Cause of ESRD²</th>
<th>All patients (n = 74)</th>
<th>AVG (n = 11)</th>
<th>AVF forearm (n = 42)</th>
<th>AVF upper arm (n = 21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertensive nephropathy, n (%)</td>
<td>27 (36)</td>
<td>7 (64)</td>
<td>12 (29)</td>
<td>8 (38)</td>
</tr>
<tr>
<td>Diabetic nephropathy, n (%)</td>
<td>26 (35)</td>
<td>6 (55)</td>
<td>11 (26)</td>
<td>9 (43)</td>
</tr>
<tr>
<td>Glomerulonephritis, n (%)</td>
<td>9 (12)</td>
<td>1 (9)</td>
<td>5 (12)</td>
<td>3 (14)</td>
</tr>
<tr>
<td>Systemic inflammatory disease and vasculitis (e.g., SLE), n (%)</td>
<td>8 (11)</td>
<td>0 (0)</td>
<td>4 (10)</td>
<td>4 (19)</td>
</tr>
<tr>
<td>Hereditary nephropathy, n (%)</td>
<td>7 (9)</td>
<td>2 (18)</td>
<td>4 (10)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Others, n (%)</td>
<td>7 (9)</td>
<td>0 (0)</td>
<td>5 (12)</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Unknown, n (%)</td>
<td>7 (9)</td>
<td>0 (0)</td>
<td>2 (5)</td>
<td>5 (24)</td>
</tr>
<tr>
<td>Tubulointerstitial nephritis, n (%)</td>
<td>4 (5)</td>
<td>2 (18)</td>
<td>2 (5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Vascular nephropathy, n (%)</td>
<td>3 (4)</td>
<td>0 (0)</td>
<td>2 (5)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Risk factors³</td>
<td>Hypertension, n (%)</td>
<td>70 (95)</td>
<td>11 (100)</td>
<td>40 (95)</td>
</tr>
<tr>
<td>Dyslipidaemia, n (%)</td>
<td>45 (61)</td>
<td>7 (64)</td>
<td>25 (60)</td>
<td>13 (62)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>36 (49)</td>
<td>7 (64)</td>
<td>16 (38)</td>
<td>13 (62)</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td>26 (35)</td>
<td>3 (27)</td>
<td>16 (38)</td>
<td>7 (33)</td>
</tr>
</tbody>
</table>

AVF = arteriovenous fistula; AVG = arteriovenous graft; BMI = body mass index; ESRD = end-stage renal disease; SLE = systemic lupus erythematosus ² At time of access creation ³ Cockroft-Gault ⁴ Multiple selections possible
formed before the vascular access was used for dialysis. Forty-one patients needed one revision, 19 patients two revisions and 8 patients three revisions.

Patients with AVG (72%) underwent more revisions compared with upper arm AVF (57%) and forearm AVF (50%). Thrombosis was the main reason for AVG revisions and stenosis for AVF revisions. Forearm AVF had more revisions due to thrombosis than upper arm AVF. Infection was observed in only one AVG. Other reasons for reoperations were banding of a high-flow fistula (one), ligation of side branches (two), intervention to correct a lymphocele (one), transposition of cephalic vein (one), and aneurysm ligation (one).

Reasons for abandonment of vascular access (31/74) were the following: spontaneous thrombosis/occlusion (12), renal transplantation (7), and death (4). Other reasons for abandonment were non-maturation (four), stenosis and hand ischaemia (two), stenosis and aneurysm (one) and multiple stenoses (one).

CVC placement

Twenty-seven patients (36%) underwent CVC placement (tunnelled or non-tunnelled) before vascular access creation. Of these, the CVC was removed in 13 (48%) patients during the first postoperative year. Of the 47 patients who did not have a CVC beforehand, 7 (15%) simultaneously received a CVC during vascular access creation and 9 (17%) received a CVC during the first year. Only 31 patients (42%) never received a CVC (fig 6.)

Thirty-seven (50%) patients had their first dialysis through a CVC. Only 19 (26%) patients had their first dialysis over an AVF and four (5%) over an AVG. At the cut-off of 365 days after surgery, 12 (16%) patients had not undergone dialysis through a catheter or a vascular access (10 AVF / 2 AVG) and 17 (23%) patients were still dialysed via a CVC. During the follow-up, in 14 patients with an AVF and in 3 patients with an AVG, the primary vascular access was never used for dialysis.

In patients with a primary AVF or AVG, the total amount of time for which a CVC was present was 380 ± 474 days (395 ± 495 days for AVF vs 262 ± 269 for AVG), which includes the pre- and post-vascular access creation period.

Discussion

During the 2-year observation period, approximately one fifth of all surgical interventions in the field of renal replacement therapy at our tertiary hospital were related to primary vascular access creation. Nearly half of this operative case-load dealt with vascular access revisions and another fifth with interventions for tunnelled CVC. Eighty-five percent of creations of primary native (autologous) vascular access was in accordance with the guidelines and reflects our policy to favour the construction of an AVF over an AVG [16]. In the case of missing forearm veins, a

![Figure 5: Secondary patency of primary vascular access: median secondary patency 458 days (interquartile range 223–767). AVF = arteriovenous fistula; AVG = arteriovenous graft](image)

![Figure 6: Central venous catheter placement in combination with vascular access creation (including 95% confidence intervals). AVF = arteriovenous fistula; AVG = arteriovenous graft](image)

<table>
<thead>
<tr>
<th>Table 2: Revisions during the follow-up.</th>
<th>All patients (n = 74)</th>
<th>AVF forearm (n = 42)</th>
<th>AVF upper arm (n = 21)</th>
<th>AV graft (n = 11)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of revisions per 1000 patient days (95% CI)</td>
<td>1.7 (1.33–2.15)</td>
<td>1.51 (1.05–2.10)</td>
<td>1.46 (0.87–2.31)</td>
<td>2.87 (1.70–4.54)</td>
<td>0.755</td>
</tr>
<tr>
<td>For bleeding</td>
<td>0.07 (0.01–0.21)</td>
<td>0.04 (0.00–0.24)</td>
<td>0.08 (0.00–0.45)</td>
<td>0.16 (0.00–0.89)</td>
<td>0.755</td>
</tr>
<tr>
<td>For stenosis</td>
<td>0.77 (0.52–1.08)</td>
<td>0.82 (0.49–1.28)</td>
<td>0.97 (0.50–1.70)</td>
<td>0.16 (0.00–0.89)</td>
<td>0.227</td>
</tr>
<tr>
<td>For thrombosis</td>
<td>0.67 (0.45–0.97)</td>
<td>0.43 (0.21–0.79)</td>
<td>0.24 (0.05–0.71)</td>
<td>2.39 (1.34–3.94)</td>
<td>0.017</td>
</tr>
<tr>
<td>For infections</td>
<td>0.02 (0.00–0.13)</td>
<td>0 (0.00–0.16)</td>
<td>0 (0.00–0.30)</td>
<td>0.16 (0.00–0.89)</td>
<td>0.632</td>
</tr>
<tr>
<td>For other reasons</td>
<td>0.17 (0.07–0.35)</td>
<td>0.22 (0.07–0.50)</td>
<td>0.16 (0.02–0.59)</td>
<td>0 (0.00–0.59)</td>
<td>0.559</td>
</tr>
</tbody>
</table>

AVF = arteriovenous fistula; AVG = arteriovenous graft; CI = confidence interval * p-value between AVG and the total of AVF (forearm and upper arm combined)
loop graft can be helpful to preserve and remodel the upper arm veins before subcutaneous AVF creation is considered [19–21]. There is an ongoing discussion as to whether for elderly patients with poor veins and a limited life expectancy, the implantation of AVG is a better option than an AVF creation, with the risk of non-maturation and the interim need for a CVC [10].

Patients with end-stage renal disease have a high prevalence of risk factors, related to a high percentage of comorbidities, particularly cardiovascular. Advanced age and poor vessel quality may be another reason why AVF maturation is a problem leading to several reinterventions even before the vascular access is in use.

The mortality from chronic kidney disease increased by 82% between 1990 and 2010 and accounts for a significant proportion of mortality in the world. This risk is dependent on the stage of the chronic kidney disease and is related to coronary heart disease [22]. Not surprisingly, this applies to our cohort with an average age of 63 years and a following drop in the survival curve.

Current literature shows a high percentage of non-maturation [23, 24], related to the fact that older patients and patients with more comorbidities are dialysed. In addition, surgeons try to promote AVF creation, even when the vessel quality seems poor. Maybe a more consistent preoperative ultrasound algorithm, based not only on the absolute arterial inner diameter, but also on the measurement of the arterial wall distensibility, could help to improve the predictability of AVF maturation [25, 26].

We observed a substantial difference in the 1-year results between the primary and the secondary patency. The primary patency rate was below our expectations and below the range of 52 to 83% reported in the literature. A Cox regression analysis did not show a significant difference between AVG and AVF.

On one hand, further investigation is needed to identify patients who are at risk for AVF non-maturation or early access failure. This is important in the context of a “firstula first” approach where surgeons are advised to create a forearm AVF instead of an AVG or upper arm AVF; even if the vessel quality is limited. On the other hand, we need improved judgement of what kind of primary access should be realised first.

Our secondary patency rates for AVF in the forearm or upper arm or for AVG is in accordance with results in the literature; showing a secondary patency for radio-cephalic AVF between 42-83% and for upper arm AVF of 47-88% [17].

This poor outcome with a consecutive need of revisions is a psychological burden for the patient and brings additional costs to the healthcare system.

It is well documented that the use of CVC has a higher morbidity and mortality [27]. Nevertheless, we recorded CVC use in up to 60% of all patients with a primary access, which is consistent with other reports [6].

In a report from the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association) registry, including 13,044 patients, an increase of CVC use to start haemodialysis from 58% in 2005 to 68% in 2009 was documented. In contrast, there was a reduction from 42 to 32% in the use of AVF as first-line vascular access [28]. In our series, 50% of all patients started their haemodialysis with a CVC. Since 36% of the CVCs were implanted before vascular access creation, this could be due to either late referral or difficulties to correctly predict optimal timing of vascular access creation. Concerning vascular access readiness for dialysis, the timing of vascular access creation and the risk of AVF non-maturation is key. Early referral is recommended: 6 months for AVF and at least 4 to 6 weeks for AVG. The increasing number of patients requiring chronic renal replacement therapy after acute kidney injury will continue to challenge optimal timing of vascular access creation. However, this inevitably can also lead to patients undergoing surgery too early, despite not requiring dialysis, as observed in our series.

This was a retrospective single-centre study with a small number of patients and medium-term follow-up, which limits comparison between the groups and generalisability of the results. The comparison of data of forearm and upper arm vascular access can be crucial when defined by the area of cannulation. The brachial artery in the antecubital fossa can give inflow for a forearm loop graft, as well as for an upper arm cephalic or basilic AVF. Therefore, the definition of the inflow vessel may be a more accurate way to categorise the vascular access than the topography of cannulation.

We assume that the group of patients in our tertiary referral centre have more comorbidities than those in smaller peripheral hospitals. For the analysis of intervention-free survival, the bias of different endpoints i.e., revisions, loss of vascular access and death, must be considered. Because of difficulties with documentation of dialysis data, it was assumed that whenever there had been a CVC placement, the patient was undergoing dialysis. Owing to lack of data, acute, acute-on-chronic and chronic kidney failure could not be differentiated in detail.

Conclusions

The primary patency in primary vascular access creation in our centre was lower than expected when compared to the literature, whereas the secondary patency was similar. The percentage of CVCs implanted for dialysis was alarmingly high and this needs to be addressed in the future, especially with regard to the ideal timing of vascular access creation. The vascular access team should implement the evidence of guidelines. There is an initiative starting this year to encourage all Swiss vascular surgeons to provide data on vascular access interventions, including 12-month follow-up, in the national online registry “SwissVasc 2.0”.

Disclosure statement
No financial support and no other potential conflict of interest relevant to this article was reported.

References
from: http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA_va_guide2.htm


